Last reviewed · How we verify
Antiarrythmic Drugs
At a glance
| Generic name | Antiarrythmic Drugs |
|---|---|
| Also known as | lidocaine |
| Sponsor | University of Sao Paulo General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antiarrhythmics or Ablation for Ventricular Tachycardia 2 (PHASE4)
- Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery (PHASE1)
- First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study) (PHASE3)
- PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN SVT (PHASE4)
- Antiarrythmic Drugs - Long-term Follow-up in the Modern Era
- Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation (PHASE3)
- Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiarrythmic Drugs CI brief — competitive landscape report
- Antiarrythmic Drugs updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI